Home » Stocks » GOSS

Gossamer Bio, Inc. (GOSS)

Stock Price: $8.25 USD -0.24 (-2.83%)
Updated Apr 19, 2021 11:32 AM EDT - Market open
Market Cap 641.23M
Revenue (ttm) n/a
Net Income (ttm) -243.36M
Shares Out 68.51M
EPS (ttm) -3.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $8.25
Previous Close $8.49
Change ($) -0.24
Change (%) -2.83%
Day's Open 8.43
Day's Range 8.22 - 8.47
Day's Volume 146,343
52-Week Range 7.92 - 16.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

3 days ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

1 month ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

4 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

5 months ago - Business Wire

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

5 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

5 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

5 months ago - Business Wire

These are the stocks seeing the most insider buying this week

YouTube video

In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.

Other stocks mentioned: MDT, SELB
6 months ago - CNBC Television

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: CERS
6 months ago - Seeking Alpha

Investors reacted forcefully Tuesday after Gossamer Bio Inc.'s (NASDAQ:GOSS) drug designated GB001 failed to achieve the hoped-for outcome in a study of patients with asthma and chronic sinus inflammati...

6 months ago - GuruFocus

Gossamer Bio Inc. (NASDAQ: GOSS) shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.

6 months ago - 24/7 Wall Street

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

6 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), today announced multiple updates for its GB004 program. GB004 is an oral, gut-targeted HIF-1α stabilizer, designed to promote mucosal heali...

6 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

6 months ago - Business Wire

Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

7 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

7 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

8 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

8 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in Gossamer Bio.

8 months ago - Zacks Investment Research

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino.

Other stocks mentioned: GLNG, GWPH, LX, NXTC, SINA, TIGO
10 months ago - Benzinga

NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 202...

10 months ago - PRNewsWire

Stock dilution is on the way for the small biotech.

10 months ago - The Motley Fool

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, AVGR, GNCA, VFF
11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Gossamer Bio

1 year ago - Zacks Investment Research

Gossamer Bio (GOSS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Gossamer Bio Inc (NASDAQ: GOSS) shares are tumbling to their lowest level since Oct.

1 year ago - Benzinga

Shares of biotech company Gossamer Bio tumbled in high volume Monday after rival pharmaceutical company Novartis scrapped an asthma treatment that failed to meet its goal in a Phase 3 study. The post T...

1 year ago - Investors Business Daily

Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.

1 year ago - The Motley Fool

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.

1 year ago - The Motley Fool

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients wi... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2019
CEO
Sheila Gujrathi
Employees
195
Stock Exchange
NASDAQ
Ticker Symbol
GOSS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Gossamer Bio stock is "Buy." The 12-month stock price forecast is 21.00, which is an increase of 154.55% from the latest price.

Price Target
$21.00
(154.55% upside)
Analyst Consensus: Buy